Skip to content

Hero image: A diverse team of women researchers reviewing clinical evidence together in a sunlit laboratory

All insights

Health systems

Closing the Evidence Gap in Women's Health Research

10 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based examination of how research funding, study design, data collection and implementation shape persistent gaps in women's health.

Evidence at a glance

7.9%

of NIH grant funding in fiscal year 2023 was classified as women's health research

The National Academies found that the share had not kept pace with overall NIH grant growth. The classification is specific to the report's methodology and should not be treated as a global funding estimate. [1]

A New Vision for Women's Health Research

The gap is broader than participation

Women now constitute roughly half or more of participants in NIH-supported clinical research, but enrollment alone does not guarantee useful evidence. Research must also ask sex-aware questions, include populations in proportions appropriate to disease burden, analyze outcomes by sex when scientifically justified, and report those analyses. A review summarized by NIH found that fewer than one third of sampled randomized trial reports analyzed data by sex, included sex in statistical models, or explained why they did not. [3]

The National Academies describes gaps across female-specific conditions, conditions that are more common in women, and diseases that affect women differently. These gaps extend from basic biology and animal models to diagnostics, longitudinal data and implementation. They are especially visible in endometriosis, fibroids, pelvic floor disorders, menopause, autoimmune disease, chronic pain and the long-term consequences of pregnancy complications. [1][2]

  • Representation should be judged against who bears the disease burden, not an automatic 50:50 target. [4]
  • Pregnancy, lactation, menstrual cycling and menopause should be considered when they are biologically or clinically relevant. [2]
  • Sex and gender are related but distinct variables and should not be used interchangeably. [3]

Funding classification reveals structural priorities

The National Academies estimated that women's health research represented 7.9% of total NIH grant funding in fiscal year 2023. It also found static funding for several female-specific conditions while total NIH grant funding grew. This measure depends on the report's definition and coding approach, yet it provides a transparent baseline for examining whether investment reflects burden, scientific opportunity and unmet need. [1]

Funding volume is only one part of research capacity. A durable response needs trained investigators, specialist cohorts, biobanks with reproductive and life-course variables, validated outcome measures, community partnerships and mechanisms that allow cross-institute work. The Academies recommended stronger NIH-wide priority setting, accountability, workforce development and a dedicated structure for women's health research. [6]

  • Track investment by condition, research stage and affected population.
  • Publish the method used to classify women's health research.
  • Pair new funding with workforce, infrastructure and data standards.

Better studies begin before recruitment

NIH's Sex as a Biological Variable policy expects applicants conducting vertebrate animal and human research to factor sex into design, analysis and reporting, or provide a scientific justification for a single-sex study. The policy addresses a historic over-reliance on male animals and cells that could obscure clinically relevant biology. It does not require every experiment to be powered for every subgroup. It requires a defensible plan. [3]

Human trials require the same discipline. An analysis of 20,020 registered interventional studies found that representation varied markedly by disease area when compared with disability burden. Cardiology and pediatrics showed particularly large negative associations with female enrollment in that analysis. The finding argues for condition-specific recruitment plans, transparent exclusions and prespecified subgroup analysis rather than a single headline enrollment percentage. [4]

  • Specify whether sex is a stratification factor, covariate, effect modifier or descriptive variable.
  • Avoid excluding pregnancy potential when risk can be managed through proportionate safeguards.
  • Report missing demographic data and explain under-representation.

Measurement must follow the whole life course

Women's health evidence is fragmented when reproductive history is separated from later chronic disease. Hypertensive disorders of pregnancy, gestational diabetes, preterm birth, early menopause and other reproductive events can be clinically relevant to later cardiovascular, metabolic and bone health. The National Academies calls for longitudinal research that connects reproductive milestones, social determinants and multimorbidity rather than treating each episode as an isolated specialty encounter. [2]

Data systems also need outcomes that matter to patients. Pain, fatigue, sexual function, fertility goals, caregiving demands, ability to work and quality of life may not be captured by laboratory endpoints alone. Measurement tools should be validated in the languages, ages and cultural groups in which they will be used. NIH's reporting shows substantial female participation overall, but aggregate totals can conceal condition-level and intersectional evidence gaps. [5]

  • Link reproductive, primary care, mental health and specialty records with consent and privacy safeguards.
  • Use patient-reported outcomes alongside biological and service outcomes.
  • Publish results by relevant age, race, ethnicity and socioeconomic groups without overinterpreting small samples.

A practical agenda for accountable progress

A credible research agenda should publish priorities, decision criteria and measurable progress. Burden of disease, severity, inequity, scientific tractability and absence of effective diagnostics or treatments are distinct considerations. Community and patient partners should help define meaningful outcomes, acceptable study burdens and the questions that have been missed. The National Academies' recommendations emphasize both biological mechanisms and the structural conditions that shape access and outcomes. [2][6]

Claims about a single dollar opportunity can distract from the harder work of evidence generation. The more useful test is whether investment produces reliable tools, representative evidence, earlier diagnosis, safer treatment and measurable improvements in health. Funding dashboards should therefore connect inputs to research outputs, validation milestones, guideline uptake and patient outcomes, while stating the time horizon and uncertainty.

  • What burden and evidence gap does the proposed study address?
  • Are participants, endpoints and follow-up appropriate to the intended population?
  • Will negative, null and subgroup findings be reported?
  • How will results change a guideline, diagnostic pathway or care decision?

What the evidence cannot yet answer

  • Funding estimates depend on definitions, coding rules and whether grants have more than one relevant purpose.
  • Aggregate enrollment does not establish adequate representation for a particular condition or subgroup.
  • Observed sex differences may reflect biology, gendered exposures, access, measurement or interactions among these factors.
  • Research investment does not guarantee clinical benefit without replication, validation and implementation.

Questions worth taking into care

  1. Does this study state why sex and gender variables are or are not relevant?
  2. Is representation compared with disease burden and the intended users of the result?
  3. Are pregnancy, menopause and reproductive history measured when clinically relevant?
  4. Are outcomes meaningful to patients as well as researchers?
  5. Are the protocol, analysis plan and limitations publicly accessible?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    A New Vision for Women's Health Research

    National Academies of Sciences, Engineering, and Medicine · 2025

  2. [2]
    Advancing Research on Chronic Conditions in Women

    National Academies of Sciences, Engineering, and Medicine · 2024

  3. [3]
  4. [4]
  5. [5]
  6. [6]
Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.